Earnings summaries and quarterly performance for Cytek Biosciences.
Executive leadership at Cytek Biosciences.
Board of directors at Cytek Biosciences.
Research analysts who have asked questions during Cytek Biosciences earnings calls.
David Westenberg
Piper Sandler
8 questions for CTKB
Also covers: ADPT, AKYA, BLLN +13 more
CW
Chad Wiatrowski
TD Cowen
7 questions for CTKB
Also covers: BLFS, CDXS, MASS +4 more
Harrison Parsons
Stephens
6 questions for CTKB
Also covers: CUTR, HOLX, PACB
Noah Lewis
Raymond James
6 questions for CTKB
Also covers: OSUR
Andrew Cooper
Raymond James
2 questions for CTKB
Also covers: AZTA, CDNA, EXAS +12 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for CTKB
Also covers: A, ADPT, AVTR +21 more
TS
Tejas Savant
Morgan Stanley
2 questions for CTKB
Also covers: ADPT, AKYA, AVTR +19 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
1 question for CTKB
Also covers: ABCL, ABSI, ARWR +19 more
MC
Mason Carrico
Stephens Inc.
1 question for CTKB
Also covers: AKYA, CDNA, CSTL +13 more
MS
Matt Sykes
Goldman Sachs Group, Inc.
1 question for CTKB
Also covers: CRL, MRVI, NTRA +4 more
YT
Yih-Ming Tu
Morgan Stanley
1 question for CTKB
Also covers: CYRX
Recent press releases and 8-K filings for CTKB.
Cytek Provides Preliminary 2025 Revenue Estimates and 2026 Growth Drivers
CTKB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Cytek estimates its 2025 total revenue to be approximately $201 million and reported $262 million in cash and marketable securities.
- For Q4 2025, the company reported preliminary product revenue of $38.1 million and service revenue of $14.2 million, noting a meaningful acceleration in year-over-year quarterly revenue growth compared to prior quarters in 2025.
- Cytek's 2025 operational highlights include 3,456 units placed, serving over 2,000 customers across more than 70 countries, and its Cytek Cloud platform grew to over 22,600 users.
- Key growth drivers for 2026 include growth in the installed base to drive service revenue, growth in reagents, innovative new products, and clinical expansion in EMEA and China.
5 days ago
Cytek Reports Preliminary 2025 Results and Strategic Outlook at JPMorgan Conference
CTKB
Revenue Acceleration/Inflection
Share Buyback
M&A
- Cytek reported preliminary full-year 2025 revenue of $201 million and Q4 2025 revenue of $62 million, with year-over-year revenue growth accelerating from -8% in Q1 2025 to 8% in Q4 2025.
- The company's revenue growth is primarily attributed to taking market share from competitors, even in a challenging market, and has seen demand stabilization in the U.S. and Europe in Q3 and Q4 2025, which is expected to continue into 2026.
- Recurring revenue from services and reagents, along with APAC instrument revenue, constitutes 50% of the overall business and experienced multi-double-digit growth in 2025, with reagent revenue growing more than 20%.
- Cytek maintains a balanced capital allocation strategy, sizing share repurchases in 2025 to approximately equal free cash flow, and is one of the few life science tool companies generating positive cash flow.
5 days ago
Cytek Biosciences Reports Preliminary 2025 Results and Outlines Growth Strategy
CTKB
Revenue Acceleration/Inflection
Share Buyback
New Projects/Investments
- Cytek Biosciences reported preliminary full-year 2025 revenue of $201 million, with Q4 2025 revenue at $62 million, representing an 8% year-over-year growth and a return to positive growth after earlier declines.
- The company's recent revenue growth is primarily driven by gaining market share from competitors, and management expects this positive momentum to continue, leading to substantial growth in 2026.
- Cytek identifies a significant opportunity in the reagent market, estimating $150 million per year in non-Cytek reagents currently used in its over 3,000 installed instruments. Reagent revenue grew over 20% in 2025, with plans to further invest in sales and marketing for reagents.
- Cytek maintains a balanced capital allocation strategy, aiming for share repurchases approximately equal to its free cash flow while also pursuing opportunistic M&A.
5 days ago
Cytek Biosciences Reports 2025 Revenue and Outlines Growth Strategy
CTKB
Revenue Acceleration/Inflection
Product Launch
M&A
- Cytek Biosciences reported $201 million in revenue for 2025, with Q4 2025 revenue reaching $62 million, representing an 8% year-over-year growth and an acceleration from earlier quarters.
- The company's growth is primarily attributed to gaining market share within a cell analysis market projected to reach $9.2 billion by 2032 with an 8.8% CAGR.
- Cytek leverages an installed base of over 3,000 instruments globally to drive recurring revenue, with reagent revenue growing over 20% in 2025.
- Key growth drivers include new product launches in 2025, such as the Aurora Evo and Guava Muse, and the expansion of the Cytek Cloud user base by over 40% by Q3 2025.
- Cytek maintains a balanced capital allocation strategy, including share repurchases approximately equal to free cash flow and opportunistic M&A, and is one of the few life science tool companies generating positive cash flow.
5 days ago
Cytek Biosciences Announces Preliminary Q4 and Full Year 2025 Revenue Results
CTKB
Earnings
Revenue Acceleration/Inflection
- Cytek Biosciences, Inc. announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025.
- The company expects total revenue for full year 2025 to be approximately $201 million.
- Fourth quarter 2025 revenue is expected to be approximately $62 million, representing 8% growth compared to Q4 2024 and 19% growth compared to Q3 2025.
- The CEO highlighted a meaningful acceleration of growth in Q4 2025, driven by strong growth in Services, Reagents, and Asia Pacific instrument revenue, and improved instrument revenue growth in the US and EMEA.
6 days ago
Cytek Biosciences Announces Preliminary Q4 and Full Year 2025 Revenue Results
CTKB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Cytek Biosciences announced preliminary, unaudited revenue of approximately $201 million for full year 2025 and approximately $62 million for the fourth quarter of 2025.
- The Q4 2025 revenue of $62 million represents 8% growth compared to Q4 2024 and 19% growth compared to Q3 2025, indicating a meaningful acceleration of growth driven by strong performance in Services, Reagents, and Asia Pacific instrument revenue, alongside improved instrument sales in the US and EMEA.
- These preliminary results are subject to adjustment, with full financial results for Q4 and FY 2025, along with 2026 financial guidance, expected near the end of February 2026.
7 days ago
Cytek Biosciences Discusses Q3 Performance, Market Growth, and New Product Adoption
CTKB
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Cytek Biosciences reported positive revenue growth in Q3 and reiterated guidance, with management suggesting a potential return to normal growth and a bottoming in the overall flow cytometry market.
- 85% of Cytek's business, encompassing service, reagents, and instruments (excluding Europe), is experiencing double-digit growth, with strong performance anticipated in Asia-Pac and stabilization in the US.
- The company launched the Aurora Evo in June, an instrument designed for pharmaceutical companies with advanced features like automated operations and higher throughput, which is expected to comprise a large majority of future instrument sales due to its price premium and capabilities.
- Reagent revenue is a key growth driver, increasing at a double-digit rate (close to 20% year-over-year), significantly outpacing the broader market's 1% growth in Q3, and represents a potential $150 million to $200 million opportunity from the installed base.
- Challenges in the European market for instrument sales in 2025 were attributed to a slowdown in biopharma spending and reduced government funding, though this segment constitutes only 15% of the total business, and the rate of decline is expected to slow in Q4 2025.
Dec 3, 2025, 2:00 PM
Cytek Discusses Q3 Performance, Aurora Evo Launch, and Reagent Growth
CTKB
Revenue Acceleration/Inflection
Product Launch
Demand Weakening
- Cytek reported positive revenue growth in Q3, with 85% of its business segments (service, reagents, and instruments excluding Europe) experiencing double-digit growth.
- The recently launched Aurora Evo instrument, tailored for pharmaceutical companies with enhanced features, is anticipated to represent a large majority of Cytek's instrument sales by 2026 and carries a price premium.
- Reagent sales demonstrated robust performance, growing at a double-digit rate, close to 20% year over year, significantly outperforming the broader market's 1% growth in Q3.
- Despite challenges in EMEA instrument sales in 2025, the company's business excluding EMEA instruments grew 11% in Q3, and EMEA reagent growth is the fastest across all territories.
Dec 3, 2025, 2:00 PM
Cytek Biosciences Discusses Q3 Performance and Market Outlook
CTKB
Revenue Acceleration/Inflection
Product Launch
Demand Weakening
- Cytek Biosciences reported positive revenue growth in Q3, with CFO Bill McCombe indicating a potential return to normal growth and a bottoming in the overall flow cytometry market.
- 85% of the business is experiencing double-digit growth, encompassing service, reagents, and instrument sales in all regions except Europe; Asia-Pac is projected for continued strong growth, and the US market is stabilizing.
- The Aurora Evo instrument, launched in June, is tailored for pharmaceutical companies, featuring capabilities like nanoparticle detection and automated operations, and is anticipated to constitute a large majority of instrument sales by 2026 at a price premium.
- Reagent growth is robust, nearing 20% year-over-year, significantly outperforming the overall market's 1% growth in Q3, with substantial future opportunities from the existing installed base.
- Instrument sales in Europe (EMEA) faced challenges in 2025 due to high prior growth in biopharma and reduced government funding, but the rate of decline is expected to slow in Q4, with easier comparisons anticipated in 2026.
Dec 3, 2025, 2:00 PM
Cytek Biosciences Reports Q3 2025 Financial Results with 2% Revenue Growth
CTKB
Earnings
Guidance Update
Demand Weakening
- Total revenue for Q3 2025 reached $52.3 million, marking a 2% year-over-year increase, primarily fueled by strong double-digit growth in the Asia-Pacific region and continued momentum in service and reagents.
- Regional performance showed APAC revenue up 25% and U.S. revenue up 12%, while EMEA experienced a 28% decline due to reduced instrument sales to academic and government customers.
- GAAP gross profit margin decreased to 53% from 56% in Q3 2024, and the company reported a net loss of $5.5 million for the quarter.
- Adjusted EBITDA was $2.5 million, down from $7.6 million in the prior year quarter, and free cash flow was -$0.3 million, with $261.7 million in cash and marketable securities.
- Cytek reaffirmed its full-year 2025 revenue outlook of $196 million-$205 million, anticipating continued strong growth in APAC instruments, stabilization in U.S. instruments, and solid growth in recurring revenue businesses.
Nov 5, 2025, 9:30 PM
Quarterly earnings call transcripts for Cytek Biosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more